<DOC>
	<DOC>NCT03001076</DOC>
	<brief_summary>The purpose of this study is to determine if bempedoic acid (ETC-1002) added-on to ezetimibe therapy is effective and safe versus placebo in patients with elevated LDL cholesterol.</brief_summary>
	<brief_title>Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Fasting LDLcholesterol greater than or equal to 100 mg/dL at screening Men and nonpregnant, nonlactating women Use of stable lipidmodifying therapy for at least 4 weeks prior to screening that includes ezetimibe 10mg daily Fasting blood triglycerides greater than or equal to 500 mg/dL Body Mass Index (BMI) greater than or equal to 50 kg/m2 Recent history of clinically significant cardiovascular disease Use of statin therapy where doses are greater than those defined as "lowdose" within 4 weeks prior to screening; where "lowdose" is defined as an average daily dose of rosuvastatin 5 mg, atorvastatin 10 mg, simvastatin 10 mg, lovastatin 20 mg, pravastatin 40 mg, fluvastatin 40 mg, or pitavastatin 2 mg.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>hyperlididemia</keyword>
	<keyword>LDL</keyword>
	<keyword>cholesterol</keyword>
	<keyword>statin intolerance</keyword>
</DOC>